NADH
16 benefits mapped to clinical evidence across supplements.
Dose per serving from products
60 products in our catalogue print how much NADH a serving holds.
Most common: 10 mg to 25 mg, 25% of 60 products.
| Dose per serving | Products |
|---|---|
| 500 mcg or less | 2 |
| 500 mcg to 1 mg | 3 |
| 1 mg to 2.5 mg | 4 |
| 2.5 mg to 5 mg | 7 |
| 5 mg to 10 mg | 12 |
| 10 mg to 25 mg | 15 |
| 25 mg to 50 mg | 13 |
| 50 mg to 100 mg | 3 |
| over 100 mg | 1 |
Benefit Evidence
Fatigue/recovery +31%
Physical function +15%
Cognition/sleep improved
Cognition, sleepiness +29%
Memory/fluency preservation
Attention lapses reduced
Better cognition, less sleepiness
ADAS-Cog ~29% better
MDRS + verbal fluency
Stress resilience: cortisol -
Stress resilience: anxiety/HR -8.1
Stress resilience: glucose/redox +10%
Stress resilience: cortisol -
Stress resilience: anxiety/HR -8.1
Stress resilience: glucose/redox +10%
Research sources
Energy & Fatigue (17)
- MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults
PubMed ID: 35182418
βNMN PK/PD study produced dose-related rises in blood NMN and NAD+ metabolites — robust pharmacodynamic support for increased cellular NAD.
- Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
PubMed ID: 36740954
Oral NMN increased blood NAD levels in overweight/obese older adults — direct evidence of NAD elevation.
- The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease
PubMed ID: 35235774
NR increased brain NAD (31P‑MRS) in Parkinson patients—direct evidence of increased cellular NAD in brain.
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
NMN produced dose‑dependent, sizable increases in blood NAD (NAD+ + NADH), consistent with raised cellular NAD pools.
- Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults
PubMed ID: 31278280
Randomized trial showed robust, dose‑dependent increases in whole blood NAD+ and related metabolites—strong biochemical evidence for increased cellular NAD availability.
- Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?
PubMed ID: 25386668
CoQ10+NADH RCT showed increased PBMC ATP and NAD+/NADH ratio — direct evidence of increased cellular energy.
- Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
PubMed ID: 34180141
CMA (including NR) increased plasma NR and NAD‑related metabolites and shifted metabolic profiles toward improved mitochondrial function.
- The differential impact of three different NAD(+) boosters on circulatory NAD and microbial metabolism in humans
PubMed ID: 41540253
Head-to-head human trial showed NR and NMN roughly doubled whole-blood NAD+ — strongest direct human evidence that precursor supplementation increases NAD pool (cellular energy substrate).
- Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial
PubMed ID: 39548320
NR increased whole-blood NAD+ in COPD patients (~+71 µM) — direct evidence of NAD pool augmentation.
- Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome
PubMed ID: 15377055
Randomized trial in chronic fatigue syndrome showed a large early reduction in fatigue symptom scores with NADH.
- Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators
PubMed ID: 37245532
Metabolic-activator cocktails including nicotinamide acutely changed NAD+-related metabolites, supporting increased cellular NAD+/energy metabolism.
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Nicotinamide improved recovery and ability to perform activities, consistent with increased perceived energy.
- Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 34444817
Large ME/CFS RCT of CoQ10+NADH reported reductions in fatigue scales (FIS‑40) and improved physical function.
- Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome - A randomized, controlled, double-blind trial
PubMed ID: 26212172
8‑week CoQ10+NADH RCT reduced patient‑reported fatigue vs placebo.
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH reduced sleepiness and cognitive deficits—direct acute increase in alertness/energy feeling.
- Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease
PubMed ID: 39657714
KL1333 showed signals for reduced fatigue/improved leg function in mitochondrial‑disease cohort.
- A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
PubMed ID: 29992272
High‑dose NR was biologically active and safe—NR directly supplies NAD+ precursors though clinical energetic outcomes were not observed.
Daily comfort (6)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
NMN produced large increases in 6MWD and SF‑36 QoL—direct evidence for improved day‑to‑day wellbeing.
- Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?
PubMed ID: 25386668
CFS trial with CoQ10+NADH reduced fatigue and oxidative stress, likely improving everyday wellbeing.
- Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
PubMed ID: 34180141
Faster clinical recovery and improved inflammatory/metabolic markers in COVID patients imply better short‑term wellbeing.
- Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 34444817
ME/CFS RCT reported improvements in fatigue, sleep and physical function and good tolerability — consistent with better daily wellbeing.
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Primary outcomes included improved ability to perform normal activities and faster recovery — directly relevant to day‑to‑day wellbeing.
- Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome
PubMed ID: 15377055
Marked early fatigue symptom improvement in CFS with NADH likely improves daily wellbeing in symptomatic individuals.
Vitality (6)
- Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?
PubMed ID: 25386668
Reduced fatigue and improved PBMC bioenergetics in CFS participants indicate enhanced vitality.
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Clinical trial showed faster recovery and better ability to perform normal activities — supports improved vitality.
- Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome
PubMed ID: 15377055
NADH produced early reduction in CFS symptoms which plausibly reflects improved overall vitality in that population.
- Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
PubMed ID: 34180141
CMA (with NR) improved clinical recovery time and systemic metabolic markers, reflecting improved vitality during illness.
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
NMN improved blood NAD, 6MWD and SF‑36 QoL—strong evidence for enhanced overall vitality in studied adults.
- Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 34444817
ME/CFS participants reported better physical function and some sleep/cognitive improvements on CoQ10+NADH.
Endurance (5)
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
PubMed ID: 38871717
NR in PAD improved 6-minute walk distance and treadmill time — direct evidence of improved walking endurance.
- Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease
PubMed ID: 39657714
KL1333 NAD(H) modulator produced a clinically relevant +2.2 reps in 30s sit‑to‑stand (improves functional endurance).
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
NMN (60 days) substantially increased six‑minute walk distance—robust signal for improved functional endurance/walking capacity.
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Large RCT of nicotinamide showed faster recovery of physical performance — supports improved endurance/physical capacity.
- Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
PubMed ID: 34238308
NMN dose‑dependently raised ventilatory threshold in recreational runners (improved submaximal endurance capacity).
Workout performance (5)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
Large improvements in 6MWD after NMN indicate better submaximal exercise performance/endurance.
- Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial
PubMed ID: 38871717
NR improved 6-minute walk distance and treadmill time in PAD — direct evidence for improved exercise performance in a patient population.
- Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
PubMed ID: 34238308
NMN increased ventilatory threshold (allows higher sustainable power/intensity) — relevant to workout performance.
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Nicotinamide led to faster recovery of physical performance — suggests potential to support workout performance indirectly.
- Optimizing rare disorder trials: a phase 1a/1b randomized study of KL1333 in adults with mitochondrial disease
PubMed ID: 39657714
KL1333 yielded a measurable functional improvement (30s sit‑to‑stand reps), a performance‑relevant outcome.
Metabolism (3)
- Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
PubMed ID: 36740954
NMN increased NAD and produced significant improvements in body weight, diastolic BP, LDL and total cholesterol in overweight/obese older adults.
- Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators
PubMed ID: 37245532
Metabolomics study of metabolic activators (including nicotinamide) directly altered NAD+-related metabolic pathways, supporting metabolic effects.
- Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19
PubMed ID: 34180141
CMA (with NR) changed inflammatory and metabolic biomarkers and shortened recovery time in COVID patients.
Sleep quality (3)
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH in travelers reduced jet‑lag sleepiness (direct evidence for less sleepiness/morning sleepiness).
- Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study
PubMed ID: 38789831
12-week NMN trial reported improved PSQI global and daytime dysfunction; directly supports better sleep.
- Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
PubMed ID: 34444817
12‑week RCT of CoQ10+NADH in ME/CFS reported increased sleep duration (between‑group at 4 weeks).
Alertness (2)
- Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
PubMed ID: 36703196
CMA including NR improved cognitive scores in mild–moderate AD, implying enhanced alertness/cognition.
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH in travelers directly reduced sleepiness and improved cognitive alertness measures.
Focus & concentration (2)
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH demonstrated improved cognitive performance and reduced sleepiness in jet‑lagged travelers (direct evidence for enhanced focus).
- Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
PubMed ID: 36703196
CMA with NR improved cognitive performance in AD (ADAS‑Cog), consistent with better focus/attention.
Mental clarity (2)
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH reduced jet‑lag cognitive deficits and sleepiness (direct evidence of clearer thinking).
- Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
PubMed ID: 36703196
Phase‑2 trial including NR showed meaningful cognitive (ADAS‑Cog) improvement versus placebo.
Exercise recovery (1)
- Nicotinamide modulates gut microbial metabolic potential and accelerates recovery in mild-to-moderate COVID-19
PubMed ID: 40355744
Primary RCT result: nicotinamide accelerated recovery of physical performance at 2 weeks — direct evidence for faster recovery.
Stress resilience (1)
- [Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome]
PubMed ID: 20447621
Oral NADH in CFS modestly reduced anxiety and lowered peak heart rate after exercise—signals improved stress/anxiety response.
Healthy aging (1)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
Functional and QoL gains after NMN were substantial and may be perceived as feeling more youthful by participants.
Motivation & confidence (1)
- The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
PubMed ID: 36482258
SF‑36 QoL improvements after NMN likely reflect improved mood/motivation components.
Memory (1)
- Combined metabolic activators improve cognitive functions in Alzheimer's disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
PubMed ID: 36703196
CMA including NR improved cognitive outcomes and preserved hippocampal subfields — directly relevant to memory.
Productivity (1)
- [Stabilized NADH (ENADA) improves jet lag-induced cognitive performance deficit]
PubMed ID: 12385067
Sublingual NADH improved several cognitive measures in jet‑lagged travelers, consistent with faster reaction/processing in that context.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with NADH
Search all84 products whose verified label declares NADH — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.